CAN-R³: Canadian Initiative to Reduce Residual Risk
1 hour

Current Dyslipidemia Management in Canada: What do the 2021 guidelines say?

This episode is part of a series. Click here to view the entire series.

CAN-R³: Canadian Initiative to Reduce Residual Risk
Broadcast Date
Presenter
Shaun Goodman, Judy Luu
Therapeutic Area
Diabetes

This virtual 3-module series is now available on demand and will provide up-to-date clinical practice information around the management of dyslipidemia for secondary prevention in patients with established ASCVD

Module 1 - Current Dyslipidemia Management in Canada: What do the 2021 guidelines say?

Featuring:

Shaun Goodman, MD, MSc, FRCPC, FACC, FAHA, FESC, FCCS
Judy Luu, MD/PhD, FRCPC

The learning objectives for this series are to:

  • Assess the care gap in lipid management in Canada and the need to prioritize LDL-C as an important modifiable risk factor (Medical Expert, Professional)
  • Apply the 2021 CCS Dyslipidemia Guidelines in clinical practice, and identify which patients will benefit the most from treatment intensification (Medical Expert, Professional)
  • Evaluate the data around siRNA therapy to prevent translation of PCSK9 messenger RNA and decrease concentrations of LDL cholesterol (Medical Expert, Professional)